secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0001213900-25-006727
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics receives Nasdaq deficiency notice for bid price below $1; 180-day cure period
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 21, 2025, for failing minimum bid price of $1.00 for 30 consecutive business days through Jan 17, 2025.
- Has until July 21, 2025 (180-day Compliance Period) to regain compliance by closing bid at $1 for at least 10 consecutive days.
- May implement reverse stock split to meet bid price requirement; must complete split no later than 10 business days before deadline.
- Also considering transfer of listing to Nasdaq Capital Market if unable to regain compliance on Global Market.
- Listing not immediately affected; company intends to monitor and take measures to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/0001213900-25-006727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/ea0228747-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-006727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer